

Supplementary Material

Table S1. Baseline characteristics of study population according to availability of HIV data

	Availability of HIV data		<i>P</i>
	No N = 898 (37.9)	Yes N = 1471 (62.1)	
Variables			
Age - median (IQR)	51 (48 - 54)	50 (47 - 54)	0.003
Male sex - n (%)	708 (78.8)	1144 (77.8)	0.54
Cirrhosis - n (%)			0.002
No	576 (64.1)	834 (56.7)	
Compensated	271 (30.2)	532 (36.2)	
Decompensated	51 (5.7)	105 (7.1)	
Prior anti-HCV therapy - n (%)			0.60
No	581 (64.7)	932 (63.4)	
Yes	317 (35.3)	538 (36.6)	
Unknown	0	1 (0.1)	
Genotype - n (%)			0.54
1			
1a	365 (40.6)	603 (41.0)	
1b	136 (15.1)	222 (15.1)	
1 non-subtyped	33 (3.7)	70 (4.8)	
2	14 (1.6)	13 (0.9)	
3	137 (15.3)	218 (14.8)	
4	206 (22.9)	324 (22.0)	
Mixed	6 (0.7)	18 (1.2)	
Indeterminate	1 (0.1)	3 (0.2)	
HCV RNA			
Known - n (%)	898 (100)	1471 (100)	
Log IU/mL - Median (IQR)	6.3 (5.8 - 6.7)	6.2 (5.8 - 6.6)	0.08

Table S2. Treatment regimens according to HCV genotype

Regimen - n (%)	G1 n = 1,429	G2 n = 27	G3 n = 355	G4 n = 530	Other* n = 28
SOF/LDV	997 (69.8)	-	83 (23.4)	366 (69.1)	21 (75.0)
SOF+DCV	55 (3.8)	5 (18.5)	264 (74.4)	18 (3.4)	4 (14.3)
DSV+OBV/PTV/r	310 (21.7)	-	-	1 (0.2)	3 (10.7)
OBV/PTV/r	4 (0.3)	-	-	128 (24.1)	-
SOF+SMV	56 (3.9)	-	-	15 (2.8)	-
SOF+RBV	2 (0.1)	22 (81.5)	8 (2.2)	-	-
SMV+DCV	3 (0.2)	-	-	1 (0.2)	-
SOF+SMV+DCV	2 (0.1)	-	-	-	-
SOF+OBV/PTV/r	-	-	-	1 (0.2)	-
Use of RBV	338 (23.6)	22 (81.5)	191 (53.8)	159 (30.0)	14 (50.0)

* Mixed genotypes 24, undetermined genotype 4.

Table S3. Treatment outcomes for HCV genotype 3 with sofosbuvir (SOF) plus daclatasvir (DCV) with or without ribavirin (RBV).

	No Cirrhosis	Compensated Cirrhosis			
	12 wks. SOF+DCV	12 wks. SOF+DCV+RBV	24 wks. SOF+DCV+RBV	24 wks. SOF+DCV	Total cirrhosis SOF+DCV
	N=119	N=11	N=48	N=17	N=83
SVR12 (ITT) - n (%)	113 (95.0)	9 (81.8)	45 (93.7)	15 (88.2)	76 (91.6)
% SVR12 (ITT) - 95% CI	89.3 - 98.1	48.2 - 97.7	82.8 - 98.7	63.6 - 98.5	83.3 - 96.5
Relapse - n (%)	3 (2.5)	0	1 (2.1)	2 (11.8)	3 (3.6)
Breakthrough - n (%)	0	1 (9.1)	0	0	1 (1.2)
D/C due to AEs - n (%)	0	0	0	0	0
D/C other reasons - n (%)	3 (2.5)	1 (9.1)	2 (4.2)	0	3 (3.6)
SVR12 (m-ITT) - n (%)	113 (97.4)	9 (90.0)	45 (97.8)	15 (88.2)	76 (95.0)
% SVR12 (m-ITT) - 95% CI	92.6 - 99.5	55.5 - 99.7	88.5 - 99.9	63.6 - 98.5	87.7 - 98.6

Table S4. Treatment outcomes for HCV genotype 3 with sofosbuvir/ledipasvir (SOF/LDV) with or without ribavirin (RBV) in patients with compensated cirrhosis.

	Compensated Cirrhosis			
	12 wks. SOF/LDV+RBV	24 wks. SOF/LDV+RBV	24 wks. SOF/LDV	Total SOF/LDV
	N=4	N=52	N=9	N=65
SVR12 (ITT) - n (%)	4 (100.0)	46 (88.5)	9 (100.0)	59 (90.8)
% SVR12 (ITT) - 95% CI	-	76.6 - 95.6	-	81.0 - 96.5
Relapse - n (%)	0	3 (5.8)	0	3 (4.6)
Breakthrough - n (%)	0	0	0	0
D/C due to AEs - n (%)	0	0	0	0
D/C other reasons - n (%)	0	1 (1.9)	0	1 (1.5)
Death	0	2 (3.8)		2 (3.1)
SVR12 (m-ITT) - n (%)	4 (100.0)	46 (90.2)	9 (100.0)	59 (92.2)
% SVR12 (m-ITT) - 95% CI	-	78.6 - 96.7	-	82.7 - 97.4

Table S5. Treatment outcomes for HCV genotype 4 with sofosbuvir/ledipasvir (SOF/LDV) or ombitasvir/paritaprevir/ribavirin (OBV/PTV/RBV) in non-cirrhotic patients.

	12 wks.	12 wks.	P
	SOF/LDV	OBV/PTV/RBV	
	N=218	N=111	
SVR12 (ITT) - n (%)	200 (91.7)	102 (91.9)	0.96
% SVR12 (ITT) - 95% CI	87.3 - 95.0	85.2 - 96.2	
Relapse - n (%)	9 (4.1)	4 (3.6)	0.82
Breakthrough - n (%)	0	1 (0.9)	0.16
D/C due to AEs - n (%)	1 (0.5)	1 (0.9)	0.63
D/C other reasons - n (%)	8 (3.7)	3 (2.7)	0.64
SVR12 (m-ITT) - n (%)	200 (95.2)	102 (94.4)	0.76
% SVR12 (m-ITT) - 95% CI	91.4 - 97.7	88.3 - 97.9	

Table S6. Treatment outcomes for HCV genotype 4 with sofosbuvir/ledipasvir (SOF/LDV) with or without ribavirin (RBV) in patients with compensated cirrhosis

	12 wks.	12 wks.	24 wks.	24 wks.	Total
	SOF/LDV	SOF/LDV+RBV	SOF/LDV	SOF/LDV+RBV	SOF/LDV
	N=28	N=13	N=74	N=1	N=116
SVR12 (ITT) - n (%)	27 (96.4)	10 (76.9)	69 (93.2)	1 (100.0)	107 (92.2)
% SVR12 (ITT) - 95% CI	81.7 - 99.9	46.2 - 95.0	84.9 - 97.8	-	85.8 - 96.4
Relapse - n (%)	1 (3.6)	2 (15.4)	4 (5.4)	0	7 (6.0)
Breakthrough - n (%)	0	0	0	0	0
D/C due to AEs - n (%)	0	0	0	0	0
D/C other reasons - n (%)	0	1 (7.7)	1 (1.4)	0	2 (1.7)
SVR12 (m-ITT) - n (%)	27 (96.4)	10 (83.3)	69 (94.5)	1 (100.0)	107 (93.9)
% SVR12 (m-ITT) - 95% CI	81.7 - 99.9	51.6 - 97.9	86.6 - 98.5	-	87.8 - 97.5

Table S7. Results from univariable and multivariable logistic regression models performed to identify independent baseline predictors of treatment failure by m-ITT analysis considering all categories of liver-disease severity (N=2318)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age		0.042		0.10
- <45	1.00		1.00	
- 45-54	1.34 (0.72 - 2.48)		1.17 (0.62 - 2.19)	
- ≥55	2.06 (1.06 - 4.00)		1.76 (0.88 - 3.49)	
Sex		0.001		0.001
- Female	1.00		1.00	
- Male	2.57 (1.46 - 4.50)		2.67 (1.51 - 4.75)	
HIV risk factor		0.55		
- Non-IDU	1.00			
- IDU	1.20 (0.63 - 2.30)			
- Other/Unknown	1.39 (0.71 - 2.72)			
CDC clinical category		0.43		
- A/B	1.00			
- C	1.21 (0.78 - 1.88)			
- Unknown	1.29 (0.87 - 1.92)			
Nadir CD4+ T-cell count - cells/mm ³		0.098		
- ≥ 200	1.00			
- < 200	1.58 (1.00 - 2.50)			
- Unknown	1.59 (0.99 - 2.55)			
Baseline CD4+ T-cell count - cells/mm ³		0.004		0.02
- ≥ 200	1.00		1.00	
- < 200	2.63 (1.46 - 4.76)		2.40 (1.29 - 4.49)	
- Unknown	1.40 (0.97 - 2.02)		1.08 (0.51 - 2.30)	
Baseline HIV RNA copies/mL		0.82		
- < 50	1.00			
- ≥ 50	1.07 (0.42 - 2.71)			
- Unknown	1.12 (0.78 - 1.62)			
cART		0.81		
- Yes	1.00			
- No	1.16 (0.35 - 3.79)			
Liver stiffness - kPa ^a		<0.001		
- < 9.5	1.00			
- 9.5 - 12.5	0.86 (0.47 - 1.57)			
- 12.6 - 19.4	0.79 (0.42 - 1.49)			
- ≥ 19.5	3.03 (2.02 - 4.54)			
- Unknown	2.68 (0.91 - 7.93)			
HCV genotype		0.22		
- 1	1.00			
- 2	3.04 (1.02 - 9.00)			
- 3	1.02 (0.61 - 1.71)			
- 4	1.35 (0.90 - 2.03)			
- Other	1.40 (0.32 - 6.01)			
HCV RNA IU/mL		0.20		0.04
- < 800,000	1.00		1.00	
- ≥ 800,000	1.29 (0.87 - 1.91)		1.53 (1.01 - 2.32)	
Naïve for anti-HCV therapy		0.48		
- Yes	1.00			
- No	1.13 (0.80 - 1.61)			
Liver disease category		<0.001		<0.001
- Non-cirrhotic	1.00		1.00 [†]	
- Compensated cirrhosis	1.71 (1.17 - 2.51)		1.50 (1.00 - 2.25) ^{†‡}	
- Decompensated cirrhosis	4.97 (3.04 - 8.14)		3.73 (2.12 - 6.58) ^{†‡}	
Anti-HCV regimen		<0.001		<0.001
- SOF/LDV	1.00		1.00	
- SOF+DCV	1.33 (0.81 - 2.18)		1.14 (0.68 - 1.90)	
- DSV+OBV/PTV/r	0.90 (0.50 - 1.62)		1.00 (0.55 - 1.81)	
- OBV/PTV/r	0.94 (0.40 - 2.21)		1.29 (0.54 - 3.10)	
- SOF+SMV	6.03 (3.33 - 10.93)		3.99 (2.09 - 7.65)	
- SOF+RBV	4.60 (1.83 - 11.56)		4.16 (1.58 - 10.96)	
- SMV+DCV	19.15 (2.66 - 138.0)		16.37 (2.11 - 126.8)	
- SOF+SMV+DCV	-		-	
- SOF+OBV/PTV/r	-		-	
Duration of anti-HCV treatment		0.11		
- 8 weeks	1.19 (0.56 - 2.52)			
- 12 weeks	1.00			
- 16 weeks	-			
- 24 weeks	1.48 (1.03 - 2.14)			
Ribavirin use		0.46		
- No	1.00			
- Yes	1.15 (0.80 - 1.65)			

[†]P=0.048; [‡]P<0.001; ^{‡‡}P=0.001.

^a Liver stiffness cutoffs: < 9.5 kPa, cutoff accurate to rule out advanced fibrosis-cirrhosis (METAVIR F3-F4); ≤ 12.5 kPa, cutoff accurate to rule out liver cirrhosis; ≤ 19.5 kPa, cutoff accurate to rule out high risk of esophageal varices.

Table S8. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by ITT analysis in non-cirrhotic patients (N = 1410)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age		0.40		
- <45	1.00			
- 45-54	1.63 (0.77 – 3.47)			
- ≥55	1.75 (0.74 – 4.14)			
Sex		0.02		0.03
- Female	1.00		1.00	
- Male	2.15 (1.13 – 4.10)		2.10 (1.09 – 4.02)	
HIV risk factor		0.21		
- Non-IDU	1.00			
- IDU	1.99 (0.84 – 4.72)			
- Other/Unknown	1.53 (0.62 – 3.76)			
CDC clinical category		0.005		0.03
- A/B	1.00		1.00	
- C	2.33 (1.37 – 3.96)		2.04 (1.19 – 3.52)	
- Unknown	1.24 (0.72 – 2.13)		1.19 (0.42 – 3.38)	
Nadir CD4+ T-cell count – cells/mm ³		0.060		
- ≥ 200	1.00			
- < 200	1.93 (1.10 – 3.40)			
- Unknown	1.33 (0.73 – 2.41)			
Baseline CD4+ T-cell count – cells/mm ³		0.001		0.006
- ≥ 200	1.00		1.00	
- < 200	4.02 (1.90 – 8.52)		3.51 (1.62 – 7.59)	
- Unknown	1.04 (0.65 – 1.66)		1.11 (0.42 – 2.95)	
Baseline HIV-1 RNA copies/mL		0.42		
- < 50	1.00			
- ≥ 50	0.32 (0.04 – 2.40)			
- Unknown	0.83 (0.52 – 1.32)			
cART		0.72		
- Yes	1.00			
- No	0.69 (0.09 – 5.16)			
Liver stiffness – kPa ^a		0.69		
- ≤ 7	1.00			
- 7.1 – 9.4	1.22 (0.66 – 2.25)			
- ≥ 9.5	0.91 (0.45 – 1.82)			
- Unknown	1.51 (0.18 – 12.57)			
HCV genotype		0.50		
- 1	1.00			
- 2	2.04 (0.46 – 9.14)			
- 3	0.76 (0.36 – 1.64)			
- 4	1.37 (0.84 – 2.23)			
- Other	1.26 (0.16 – 9.81)			
HCV RNA IU/mL		0.087		0.09
- < 800,000	1.00		1.00	
- ≥ 800,000	1.59 (0.93 – 2.71)		1.59 (0.93 – 2.72)	
Naïve for anti-HCV therapy		0.60		
- Yes	1.00			
- No	0.88 (0.55 – 1.42)			
Anti-HCV regimen		0.36		
- SOF/LDV	1.00			
- SOF+DCV	0.66 (0.31 – 1.40)			
- DSV+OBV/PTV/r	0.58 (0.28 – 1.20)			
- OBV/PTV/r	1.13 (0.54 – 2.34)			
- SOF+SMV	-			
- SOF+RBV	1.99 (0.44 – 8.94)			
- SMV+DCV	-			
- SOF+SMV+DCV	-			
- SOF+OBV/PTV/r	-			
Duration of anti-HCV treatment		0.33		
- 8 weeks	1.10 (0.54 – 2.26)			
- 12 weeks	1.00			
- 16 weeks	-			
- 24 weeks	0.23 (0.03 – 1.68)			
Ribavirin use		0.75		
- No	1.00			
- Yes	0.92 (0.54 – 1.55)			

^a Liver stiffness cutoff: ≤ 7 kPa, cutoff to rule out no or mild fibrosis; < 9.5 kPa, cutoff to rule out advanced fibrosis-cirrhosis.

Table S9. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by m-ITT analysis in patients without cirrhosis (N = 1380)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age		0.57		
- <45	1.00			
- 45-54	1.11 (0.49 - 2.54)			
- ≥55	1.53 (0.60 - 3.91)			
Sex		0.01		0.01
- Female	1.00		1.00	
- Male	3.24 (1.28 - 8.17)		3.25 (1.29 - 8.21)	
HIV risk factor		0.79		
- Non-IDU	1.00			
- IDU	1.40 (0.54 - 3.66)			
- Other/Unknown	1.38 (0.51 - 3.71)			
CDC clinical category		0.42		
- A/B	1.00			
- C	1.57 (0.80 - 3.08)			
- Unknown	1.25 (0.67 - 2.34)			
Nadir CD4+ T-cell count - cells/mm ³		0.72		
- ≥ 200	1.00			
- < 200	1.32 (0.67 - 2.59)			
- Unknown	1.22 (0.62 - 2.40)			
Baseline CD4+ T-cell count - cells/mm ³		0.29		
- ≥ 200	1.00			
- < 200	2.39 (0.81 - 7.08)			
- Unknown	1.09 (0.63 - 1.91)			
Baseline HIV-1 RNA copies/mL		0.93		
- < 50	1.00			
- ≥ 50	-			
- Unknown	0.98 (0.56 - 1.70)			
cART		-		
- Yes	1.00			
- No	-			
Liver stiffness - kPa ^a		0.86		
- ≤ 7	1.00			
- 7.1 - 9.4	0.92 (0.45 - 1.86)			
- ≥ 9.5	0.83 (0.37 - 1.83)			
- Unknown	1.93 (0.23 - 16.28)			
HCV genotype		0.30		
- 1	1.00			
- 2	2.86 (0.63-12.93)			
- 3	0.40 (0.12 - 1.32)			
- 4	1.14 (0.62 - 2.08)			
- Other	1.76 (0.22 - 13.84)			
HCV RNA IU/mL		0.11		0.10
- < 800,000	1.00		1.00	
- ≥ 800,000	1.74 (0.89 - 3.39)		1.75 (0.89 - 3.41)	
Naïve for anti-HCV therapy		0.87		
- Yes	1.00			
- No	0.96 (0.54 - 1.69)			
Anti-HCV regimen		0.25		
- SOF/LDV	1.00			
- SOF+DCV	0.39 (0.12 - 1.27)			
- DSV+OBV/PTV/r	0.81 (0.37 - 1.77)			
- OBV/PTV/r	1.18 (0.49 - 2.85)			
- SOF+SMV	-			
- SOF+RBV	3.11 (0.68 - 14.20)			
- SMV+DCV	-			
- SOF+SMV+DCV	-			
- SOF+OBV/PTV/r	-			
Duration of anti-HCV treatment		0.30		
- 8 weeks	1.57 (0.73 - 3.41)			
- 12 weeks	1.00			
- 16 weeks	-			
- 24 weeks	0.37 (0.05 - 2.72)			
Ribavirin use		0.83		
- No	1.00			
- Yes	1.07 (0.58 - 1.98)			

^a Liver stiffness cutoff: ≤ 7 kPa, cutoff to rule out no or mild fibrosis; < 9.5 kPa, cutoff to rule out advanced fibrosis-cirrhosis.

Table S10. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by ITT analysis in patients with compensated cirrhosis (N=803)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age		0.07		0.03
- <45	1.00		1.00	
- 45-54	1.64 (0.57 – 4.71)		1.55 (0.53 – 4.56)	
- ≥55	2.74 (0.92 – 8.18)		2.99 (0.97 – 9.19)	
Sex		0.71		
- Female	1.00			
- Male	1.13 (0.59 – 2.16)			
HIV risk factor		0.04		
- Non-IDU	1.00			
- IDU	0.76 (0.29 – 2.02)			
- Other/Unknown	1.49 (0.55 – 4.04)			
CDC clinical category		0.01		
- A/B	1.00			
- C	1.47 (0.78 – 2.76)			
- Unknown	2.37 (1.33 – 4.22)			
Nadir CD4+ T-cell count – cells/mm ³		0.01		
- ≥ 200	1.00			
- < 200	1.61 (0.81 – 3.21)			
- Unknown	2.75 (1.37 – 5.52)			
Baseline CD4+ T-cell count – cells/mm ³		0.02		
- ≥ 200	1.00			
- < 200	1.85 (0.78 – 4.39)			
- Unknown	2.07 (1.24 – 3.46)			
Baseline HIV RNA copies/mL		0.05		
- < 50	1.00			
- ≥ 50	1.58 (0.53 – 4.68)			
- Unknown	1.88 (1.13 – 3.15)			
cART		0.22		
- Yes	1.00			
- No	2.23 (0.62 – 7.94)			
Liver stiffness – kPa ^a		<0.001		0.001
- < 19.5	1.00		1.00	
- ≥ 19.5	3.32 (1.84 – 5.98)		3.03 (1.65 – 5.54)	
- Unknown	2.05 (0.25 – 16.97)		1.41 (0.16 – 12.22)	
HCV genotype		0.23		
- 1	1.00			
- 2	-			
- 3	1.33 (0.71 – 2.49)			
- 4	1.67 (0.92 – 3.03)			
- Other	3.03 (0.62-14.81)			
HCV RNA IU/mL		0.25		0.096
- < 800,000	1.00		1.00	
- ≥ 800,000	1.39 (0.80 – 2.42)		1.65 (0.91 – 2.96)	
Naïve for anti-HCV therapy		0.56		
- Yes	1.00			
- No	0.86 (0.53 – 1.42)			
Anti-HCV regimen		0.001		0.01
- SOF/LDV	1.00		1.00	
- SOF+DCV	1.87 (1.00 – 3.48)		1.79 (0.94 – 3.38)	
- DSV+OBV/PTV/r	1.18 (0.51 – 2.75)		1.20 (0.51 – 2.85)	
- OBV/PTV/r	1.23 (0.15 – 9.79)		1.60 (0.19 – 13.30)	
- SOF+SMV	5.20 (2.33 – 11.63)		4.22 (1.82 – 9.78)	
- SOF+RBV	4.51 (0.88 – 23.15)		5.33 (0.94 – 30.20)	
- SMV+DCV	-		-	
- SOF+SMV+DCV	-		-	
- SOF+OBV/PTV/r	-		-	
Duration of anti-HCV treatment		0.93		
- 8 weeks	-			
- 12 weeks	1.00			
- 16 weeks	-			
- 24 weeks	0.98 (0.60 – 1.60)			
Ribavirin use		0.99		
- No	1.00			
- Yes	1.00 (0.61 – 1.64)			

^a Liver stiffness cutoff: ≤ 19.5 kPa, cutoff accurate to rule out high-risk of esophageal varices.

Table S11. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by m-ITT analysis in patients with compensated cirrhosis (N=785)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age		0.14		0.10
- <45	1.00		1.00	
- 45-54	5.53 (0.75 - 40.92)		5.40 (0.71 - 41.00)	
- ≥55	7.31 (0.95 - 56.15)		7.97 (1.01 - 63.23)	
Sex		0.31		
- Female	1.00			
- Male	1.52 (0.67 - 3.44)			
HIV risk factor		0.04		
- Non-IDU	1.00			
- IDU	0.54 (0.20 - 1.46)			
- Other/Unknown	1.13 (0.41 - 3.13)			
CDC clinical category		0.04		
- A/B	1.00			
- C	0.89 (0.42 - 1.89)			
- Unknown	1.99 (1.07 - 3.73)			
Nadir CD4+ T-cell count - cells/mm ³		0.02		
- ≥ 200	1.00			
- < 200	1.57 (0.71 - 3.48)			
- Unknown	2.81 (1.27 - 6.22)			
Baseline CD4+ T-cell count - cells/mm ³		0.01		0.04
- ≥ 200	1.00		1.00	
- < 200	2.65 (1.09 - 6.48)		2.75 (1.07 - 7.08)	
- Unknown	2.23 (1.23 - 4.04)		1.96 (1.04 - 3.66)	
Baseline HIV RNA copies/mL		0.06		
- < 50	1.00			
- ≥ 50	2.16 (0.72 - 6.50)			
- Unknown	1.91 (1.06 - 3.44)			
cART		0.38		
- Yes	1.00			
- No	1.97 (0.44 - 8.90)			
Liver stiffness - kPa ^a		<0.001		0.01
- < 19.5	1.00		1.00	
- ≥ 19.5	3.83 (1.89 - 7.73)		3.04 (1.46 - 6.29)	
- Unknown	3.08 (0.36 - 26.23)		1.49 (0.16 - 13.86)	
HCV genotype		0.27		
- 1	1.00			
- 2	-			
- 3	1.34 (0.65 - 2.76)			
- 4	1.90 (0.98 - 3.69)			
- Other	2.08 (0.25 - 17.23)			
HCV RNA IU/mL		0.76		
- < 800,000	1.00			
- ≥ 800,000	1.10 (0.60 - 2.01)			
Naïve for anti-HCV therapy		0.78		
- Yes	1.00			
- No	1.08 (0.62 - 1.89)			
Anti-HCV regimen		<0.001		<0.001
- SOF/LDV	1.00		1.00	
- SOF+DCV	2.37 (1.17 - 4.82)		2.02 (0.97 - 4.22)	
- DSV+OBV/PTV/r	1.59 (0.63 - 4.02)		1.90 (0.73 - 4.94)	
- OBV/PTV/r	-		-	
- SOF+SMV	8.14 (3.51 - 18.88)		6.25 (2.57 - 15.20)	
- SOF+RBV	7.06 (1.35 - 36.90)		7.60 (1.30 - 44.31)	
- SMV+DCV	-		-	
- SOF+SMV+DCV	-		-	
- SOF+OBV/PTV/r	-		-	
Duration of anti-HCV treatment		0.50		
- 8 weeks	-			
- 12 weeks	1.00			
- 16 weeks	-			
- 24 weeks	0.83 (0.47 - 1.44)			
Ribavirin use		0.85		
- No	1.00			
- Yes	0.95 (0.54 - 1.67)			

^a Liver stiffness cutoff: ≤ 19.5 kPa, cutoff accurate to rule out high-risk of esophageal varices.

Table S12. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by ITT analysis in patients with decompensated cirrhosis (N=156)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age				
– <45	1.00	0.19		
– 45-54	0.37 (0.10 – 1.37)			
– ≥55	0.69 (0.17 – 2.86)			
Sex				
– Female	1.00	0.045	1.00	0.079
– Male	3.14 (1.03 – 9.58)		2.94 (0.88 – 9.81)	
HIV risk factor				
– Non-IDU	1.00	0.84		
– IDU	1.43 (0.29 – 6.97)			
– Other/Unknown	1.16 (0.21 – 6.27)			
CDC clinical category				
– A/B	1.00	0.84		
– C	1.07 (0.41 – 2.80)			
– Unknown	0.78 (0.29 – 2.09)			
Nadir CD4+ T-cell count – cells/mm ³				
– ≥ 200	1.00	0.79		
– < 200	0.83 (0.30 – 2.27)			
– Unknown	0.67 (0.21 – 2.14)			
Baseline CD4+ T-cell count – cells/mm ³				
– ≥ 200	1.00	0.90		
– < 200	1.22 (0.36 – 4.16)			
– Unknown	1.20 (0.50 – 2.90)			
Baseline HIV RNA copies/mL				
– < 50	1.00	0.72		
– ≥ 50	2.00 (0.17 – 23.07)			
– Unknown	0.78 (0.31 – 1.98)			
cART				
– Yes	1.00	0.53		
– No	1.73 (0.32 – 9.37)			
Liver stiffness – kPa ^a				
– < 19.5	1.00	0.56		
– ≥ 19.5	1.85 (0.59 – 5.81)			
– Unknown	1.91 (0.37 – 9.95)			
HCV genotype				
– 1	1.00	0.29		
– 2	9.62 (0.82 – 112.67)			
– 3	1.60 (0.55 – 4.67)			
– 4	1.11 (0.39 – 3.14)			
– Other	-			
HCV RNA IU/mL				
– < 800,000	1.00	0.089	1.00	0.097
– ≥ 800,000	2.06 (0.90 – 4.76)		2.12 (0.87 – 5.16)	
Naïve for anti-HCV therapy				
– Yes	1.00	0.54		
– No	1.29 (0.57 – 2.88)			
Anti-HCV regimen				
– SOF/LDV	1.00	0.36		
– SOF+DCV	1.00 (0.35 – 2.87)			
– DSV+OBV/PTV/r	-			
– OBV/PTV/r	-			
– SOF+SMV	1.90 (0.66 – 5.43)			
– SOF+RBV	3.09 (0.66 – 14.57)			
– SMV+DCV	-			
– SOF+SMV+DCV	-			
– SOF+OBV/PTV/r	-			
Duration of anti-HCV treatment				
– 8 weeks	-	0.64		
– 12 weeks	1.00			
– 16 weeks	-			
– 24 weeks	0.81 (0.34 – 1.95)			
Ribavirin use				
– No	1.00	0.99		
– Yes	0.99 (0.45 – 2.21)			
History of hepatocellular carcinoma				
– Yes	1.00	0.03	1.00	0.04
– No	3.18 (1.12 – 9.07)		3.32 (1.06 – 10.42)	
Child-Pugh-Turcotte score				
– A	1.00	0.02	1.00	0.009
– B	1.66 (0.70 – 3.94)		1.85 (0.74 – 4.65)	
– C	7.84 (1.82 – 33.79)		12.01 (2.44 – 59.03)	
MELD score ^b				
– ≤ 7	1.00	0.28		
– > 7	1.88 (0.60 – 5.83)			
– Unknown	-			

^a Liver stiffness cutoff: ≤ 19.5 kPa, cutoff accurate to rule out high-risk of esophageal varices.

^b 7 was the median value of the MELD score

Table S13. Results from univariable and multivariable logistic regression models to identify independent baseline predictors of treatment failure by m-ITT analysis in patients with decompensated cirrhosis (N=153)

Variable	Univariable		Multivariable	
	OR (95% CI)	P	OR (95% CI)	P
Age				
– <45	1.00	0.09		
– 45-54	0.30 (0.08 – 1.15)			
– ≥55	0.69 (0.17 – 2.86)			
Sex				0.04
– Female	1.00	0.018	1.00	
– Male	6.03 (1.36 – 26.69)		5.04 (1.07 – 23.69)	
HIV risk factor		0.58		
– Non-IDU	1.00			
– IDU	2.71 (0.33 – 22.34)			
– Other/Unknown	2.03 (0.22 – 18.29)			
CDC clinical category		0.73		
– A/B	1.00			
– C	1.23 (0.46 – 3.29)			
– Unknown	0.77 (0.27 – 2.20)			
Nadir CD4+ T-cell count – cells/mm ³		0.77		
– ≥ 200	1.00			
– < 200	1.16 (0.38 – 3.52)			
– Unknown	0.8 (0.22 – 2.92)			
Baseline CD4+ T-cell count – cells/mm ³		0.83		
– ≥ 200	1.00			
– < 200	1.39 (0.40 – 4.82)			
– Unknown	1.23 (0.49 – 3.11)			
Baseline HIV RNA copies/mL		0.65		
– < 50	1.00			
– ≥ 50	2.20 (0.19 – 25.47)			
– Unknown	0.73 (0.27 – 1.98)			
cART		0.95		
– Yes	1.00			
– No	0.93 (0.10 – 8.30)			
Liver stiffness – kPa ^a		0.65		
– < 19.5	1.00			
– ≥ 19.5	1.69 (0.53 – 5.34)			
– Unknown	1.27 (0.20 – 7.97)			
HCV genotype		0.27		
– 1	1.00			
– 2	11.0 (0.93 – 129.7)			
– 3	1.53 (0.49 – 4.79)			
– 4	1.27 (0.44 – 3.64)			
– Other	-			
HCV RNA IU/mL		0.10		
– < 800,000	1.00			
– ≥ 800,000	2.06 (0.86 – 4.94)			
Naïve for anti-HCV therapy		0.49		
– Yes	1.00			
– No	1.34 (0.58 – 3.12)			
Anti-HCV regimen		0.43		
– SOF/LDV	1.00			
– SOF+DCV	1.18 (0.40 – 3.48)			
– DSV+OBV/PTV/r	-			
– OBV/PTV/r	-			
– SOF+SMV	2.24 (0.77 – 6.58)			
– SOF+RBV	2.44 (0.42 – 14.15)			
– SMV+DCV	-			
– SOF+SMV+DCV	-			
– SOF+OBV/PTV/r	-			
Duration of anti-HCV treatment		0.43		
– 8 weeks	-			
– 12 weeks	1.00			
– 16 weeks	-			
– 24 weeks	0.70 (0.28 – 1.70)			
Ribavirin use		0.57		
– No	1.00			
– Yes	0.78 (0.34 – 1.82)			
History of hepatocellular carcinoma		0.016		0.03
– Yes	1.00		1.00	
– No	3.66 (1.27 – 10.56)		3.61 (1.16 – 11.25)	
Child-Pugh-Turcotte score		0.045		0.02
– A	1.00		1.00	
– B	1.69 (0.69 – 4.16)		1.98 (0.76 – 5.18)	
– C	6.9 (1.48 – 32.07)		10.44 (1.97 – 55.22)	
MELD score ^b		0.38		
– ≤ 7	1.00			
– > 7	1.66 (0.53 – 5.20)			
– Unknown	-			

^a Liver stiffness cutoff: ≤ 19.5 kPa, cutoff accurate to rule out high-risk of esophageal varices.

^b 7 was the median value of the MELD score